Certara, Inc. (NASDAQ:CERT) Short Interest Down 7.5% in November

Certara, Inc. (NASDAQ:CERT) saw a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 4,960,000 shares, a decrease of 7.5% from the October 31st total of 5,360,000 shares. Based on an average daily volume of 1,300,000 shares, the days-to-cover ratio is presently 3.8 days. Currently, 4.5% of the company’s shares are sold short.

Certara Stock Up 0.7 %

Shares of Certara stock traded up $0.08 on Monday, reaching $11.29. 2,044,888 shares of the company were exchanged, compared to its average volume of 805,984. The stock’s 50 day moving average price is $10.81 and its 200-day moving average price is $12.98. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The company has a market cap of $1.82 billion, a P/E ratio of -56.45, a price-to-earnings-growth ratio of 5.67 and a beta of 1.51. Certara has a 1-year low of $9.41 and a 1-year high of $19.87.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm had revenue of $94.80 million during the quarter, compared to analysts’ expectations of $95.51 million. During the same quarter in the prior year, the business posted $0.06 earnings per share. Certara’s revenue was up 10.7% compared to the same quarter last year. As a group, equities analysts forecast that Certara will post 0.28 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on CERT. Barclays decreased their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Robert W. Baird cut their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Finally, UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Friday, September 27th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $15.92.

Insiders Place Their Bets

In related news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the sale, the insider now owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. The trade was a 33.94 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the sale, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. This trade represents a 9.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.39% of the company’s stock.

Institutional Trading of Certara

Several hedge funds have recently added to or reduced their stakes in the business. Barclays PLC boosted its position in shares of Certara by 198.3% during the third quarter. Barclays PLC now owns 70,525 shares of the company’s stock worth $825,000 after buying an additional 46,880 shares during the period. Jane Street Group LLC lifted its stake in shares of Certara by 2.6% in the 3rd quarter. Jane Street Group LLC now owns 147,393 shares of the company’s stock worth $1,726,000 after acquiring an additional 3,732 shares during the period. State Street Corp raised its stake in shares of Certara by 3.4% in the third quarter. State Street Corp now owns 3,679,699 shares of the company’s stock worth $43,089,000 after acquiring an additional 122,411 shares during the last quarter. Petrus Trust Company LTA bought a new position in shares of Certara in the third quarter valued at about $994,000. Finally, Paloma Partners Management Co acquired a new stake in Certara in the 3rd quarter valued at $413,000. Institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.